Announcement on Resolutions of the 14th Extraordinary Meeting of the 9th Board of Directors
Stock abbreviation: Huahai Pharmaceutical Stock code: 600521 Announcement number: Lin 2026-082 Bond abbreviation: Huahai convertible bonds Bond code: 110076
Zhejiang Huahai Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 14th Extraordinary Meeting of the Ninth Board of Directors
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
The 14th extraordinary meeting of the 9th board of directors of Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held by communication in the company's conference room at 9:00 am on July 15, 2026. Nine directors should be present at the meeting, but nine directors actually attended the meeting, which complied with the quorum for convening a board meeting. The meeting was chaired by Mr. Li Hong, chairman of the company. The meeting procedures complied with the provisions of the Company Law and the Articles of Association, and the meeting was legal and valid. The meeting reviewed and passed the following resolutions:
1. The “Proposal on the Appointment of Senior Management Personnel of the Company” was reviewed and approved
Voting results: Agree: 9 votes; oppose: 0 votes; abstain: 0 votes.
Meeting resolution: Based on the company's development needs, the board of directors agreed to appoint Mr. Xu Xuejian as the company's vice president and chief quality officer, who will be fully responsible for the company's quality management and analysis and testing work. His term will last until the expiration of the company's ninth session of the board of directors.
The proposal has been reviewed and approved at the fourth meeting of the Human Resources Committee of the ninth session of the Board of Directors of the company, and has been reviewed and approved by the company's current board of directors.
Announcement is hereby made.
Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd.
July 15, 2026
Attached: Resumes of the company’s senior managers
Mr. Xu Xuejian: Starting from June 2026, he will work at Zhejiang Huahai Pharmaceutical Co., Ltd. as the company’s vice president and chief quality officer. Before joining the company, Mr. Xu Xuejian served as Vice President and Chief Quality Officer of Jiangsu Hengrui Pharmaceutical Co., Ltd.; Senior Vice President and Chief Quality Officer of WuXi Biotechnology Co., Ltd.; WuXi WuXi AppTec
1/2
Vice President of the Quality Department and the U.S. Drug Administration Department of New Drug Development Co., Ltd.; drug review reviewer of the Office of Generic Drugs of the U.S. Food and Drug Administration (FDA).
Mr. Xu Xuejian holds a PhD in organic chemistry from Northeastern University, a graduate student from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and a bachelor's degree from East China University of Science and Technology.
As of now, Mr. Xu Xuejian does not hold any shares in the company. There is no related relationship between Mr. Xu Xuejian and the actual controller of the company, shareholders holding more than 5% of the shares and other directors and senior managers of the company. There is no situation in which he is not allowed to be nominated as a senior manager in the "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 1 - Standardized Operations". He has not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by the stock exchange. He meets the conditions for senior managers stipulated in laws, regulations and normative documents.
2/2